Precise. Personalized. Predictive.
Venebio Opioid Advisor Clinical Decision Support
Over the last two decades, prescription opioid-related overdose and deaths from opioid-induced respiratory depression (OIRD) have emerged as a major public health threat in the United States. Overdose deaths involving prescription opioids have quadrupled since 1999 and parallel the striking increase of U.S. sales and consumption of prescription opioids. From 1999 to 2015, more than 183,000 people have died in the U.S. from overdoses related to prescription opioids.
More about the opioid overdose epidemic.
In response to the public health threat posed by the opioid overdose epidemic, Venebio Group developed the Venebio Opioid Advisor (VOA) clinical decision support tool to support safer opioid prescribing.
The tool provides an evidence-based, quantitative estimate of a patient’s likelihood of experiencing a life-threatening opioid emergency in the next six months. It characterizes the patient’s specific risk factor profile and provides individualized, evidence-based, risk-mitigation interventions for the health care professional and patient.
More about Venebio Opioid Advisor.
The development of VOA built on our previously published predictive models and scoring systems that estimate the level of risk of experiencing an adverse outcome.
VOA has undergone extensive retrospective validation, initially in a case-control study of U.S. military veterans, followed by validation in a more representative population using the IMS PharMetrics Plus™ database of 18+ million prescription opioid users.
Implementing VOA can prevent more than 500 overdoses per 100,000 opioid recipients per year. This translates into preventing over 400 prescription opioid overdose-related emergency department visits, avoiding over 120 hospitalizations, and reducing annual health care costs by $2 million per 100,000 patients receiving opioid therapy.
More about our research.
In this serial cross-sectional study published in JAMA, researchers found that the percentage of all deaths attributable to opioids increased 292% (from 0.4% to 1.5%) between 2001 and 2016, resulting in approximately 1.68 million person-years of life lost in 2016 alone (5.2 per 1000 population). The burden was particularly high […]
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held its annual conference in Baltimore, Md. on May 19-23, and Venebio consultant, Carlos H. Rojas-Fernandez, PharmD attended to gather insights on recent developments and trends in the industry. Rojas-Fernandez’s notes that there were a number of posters from Alkermes in the area […]
Today, U.S. Surgeon General Jerome M. Adams, M.D., M.P.H., urged more Americans to carry a lifesaving medication that can reverse the effects of an opioid overdose. The medication, naloxone, is already carried by many first responders, such as EMTs and police officers. The Surgeon General is now recommending that more individuals, including […]
PrescribeWellness and Venebio are working together to flight the opioid crisis. With network reach of over 200 million lives, PrescribeWellness is uniquely positioned to arm the most accessible healthcare professionals in the communities — pharmacists — with VOA, the only validated tool able to predict the likelihood of a life-threatening […]
RICHMOND, Va. – January 31, 2018 – The New Hampshire Board of Medicine has approved Venebio Opioid Advisor™ (VOA™) as one of the state’s official risk assessment tools for opioid prescribing. New Hampshire state law requires that any opioid risk assessment tool be approved by the New Hampshire Board of Medicine. The […]
Comprehensive analysis of U.S. prescription opioid users and overdose cases further supports personalized approach to prescription of opioids. RICHMOND, Va. – January 15, 2017 – Individuals suffering from a substance use disorder (SUD) or depression are among those at highest risk for a serious prescription opioid overdose, according to a study […]